A gene borrowed from the naked mole rat, an animal famous for extraordinary longevity and disease resistance, helped mice live a little longer and stay healthier, pointing to a surprising biological ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. When Kulindu Vithanachchi’s phone lit up with an update from the National Science ...

Generative and agentic artificial intelligence may be positioned to reshape the life sciences and healthcare (LSHC) landscape in 2026 and beyond. However, realizing the technology’s full ...

Artificial intelligence is no longer a promise of the future in the life sciences. It is quickly becoming a core competency for launching, scaling, and sustaining therapies. As the volume of data ...

A Dalai Lama once said that our prime purpose in this life is to help others – and he may have been right. Scientists have found that having a positive impact on other people seems to be a key element ...

British Land has agreed to acquire Life Science REIT in a recommended cash-and-share deal valuing the specialist property investor at about £150M. The deal represents a premium of about 21% to Life ...

European investment firm Gimv will no longer put funds into the life sciences sector, choosing instead to focus on its long-term investments and finding new value in four other key areas. The decision ...

After two years of layoffs and funding pullbacks, South San Francisco’s life science industry is showing stronger signs of a comeback— though more mega-rounds and less early-stage funding could ...

BlueRidge Life Sciences (“BlueRidge”), a leading life sciences consulting and services platform and a portfolio company of Renovus Capital Partners, today announced the acquisition of Design Science, ...

Chiba, Japan, January 12, 2026—A team at Japan’s National Institutes for Quantum Science and Technology (QST) has published a field-defining Perspective that places the societal payoff of quantum ...

Life sciences mergers and acquisitions surged back in force in 2025, as pharmaceutical and med-tech companies moved aggressively to shore up pipelines and offset looming revenue losses, according to ...